文档介绍：JOURNAL OF RARE AND UNCOMMON DISEASES, JUN. 2022,, , Total
·论著·
依帕司他联合硫辛酸治疗糖尿病周围神经病变患者临床疗效研increase in the study group was greater than
that in the control group (P<). The scores of MDA, TSS and TCSS of the two groups decreased after treatment, and the decrease of the study
group was greater than that of the control group (P<). The effective rate of the two groups was compared (% VS. %), and the
difference was significant (t=, P=). Conclusion Epalrestat combined with lipoic acid in the treatment of diabetic peripheral neuropathy
can help to inhibit oxidative stress, improve the therapeutic effect, and improve the patient's nerve function.
Keywords: Epalrestat; Lipoic Acid; Diabetic Peripheral Neuropathy; Clinical Efficacy
糖尿病周围神经病变(diabetic peripheral 一般资料 择取深圳市职业病防治院2019年3月至2021
neuropathy，DPN)是糖尿病患者极易罹患的慢性并发症 年2月收治的114例DPN患者进行本次研究，采用电脑抽签
之一，对患者健康造成了较大威胁。DPN患者神经受到毁 法进行随机分组，将其分为对照组(n=57例)和研究组(n=57
损，感觉系统会发生异常，对疼痛、外伤不能进行预防性的 例)。对照组男性33例，女性24例；年龄41~74岁，平均
保护，当出现合并感染时易导致糖尿病足，增加高危截肢风 年龄(±)岁；糖尿病病程1~12年，平均病程
[1]
险 。研究数据显示，DPN患者截肢的风险比正常人群高 (6